The pharmacological inhibition of NOS by l-NMMA (NG-Monomethyl-l-arginine) has been reported to enhance chemotherapy response in triple negative breast cancer (TNBC) models, significantly reducing tumor volume growth and increasing the survival rate [47]. The gene discussed is NOS2; the disease is triple-negative breast carcinoma.